ABBVIE INC (ABBV) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:ABBV - US00287Y1091 - Common Stock
ABBV Key Statistics, Chart & Performance
The current stock price of ABBV is 214.35 USD. In the past month the price decreased by -4.44%. In the past year, price increased by 24.94%.
ABBV Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ABBV. When comparing the yearly performance of all stocks, ABBV turns out to be only a medium performer in the overall market: it outperformed 64.2% of all stocks.
ABBV Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ABBV. ABBV scores excellent on profitability, but there are concerns on its financial health.
ABBV Financial Highlights
Over the last trailing twelve months ABBV reported a non-GAAP Earnings per Share(EPS) of 9.45. The EPS decreased by -12.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3.94% | ||
| ROA | 1.75% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ABBV Forecast & Estimates
37 analysts have analysed ABBV and the average price target is 249.74 USD. This implies a price increase of 16.51% is expected in the next year compared to the current price of 214.35.
For the next year, analysts expect an EPS growth of 7.3% and a revenue growth 8.74% for ABBV
ABBV Ownership
ABBV Latest News, Press Relases and Analysis
ABBV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.44B |
Related stock screener links
About ABBV
Company Profile
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 55,000 full-time employees. The company went IPO on 2013-01-02. The company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
Company Info
ABBVIE INC
1 N Waukegan Rd
North Chicago ILLINOIS 60064 US
CEO: Richard A. Gonzalez
Employees: 55000
Phone: 18479327900
ABBVIE INC / ABBV FAQ
Can you describe the business of ABBVIE INC?
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 55,000 full-time employees. The company went IPO on 2013-01-02. The company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
What is the stock price of ABBVIE INC today?
The current stock price of ABBV is 214.35 USD. The price decreased by -1.11% in the last trading session.
What is the dividend status of ABBVIE INC?
ABBVIE INC (ABBV) has a dividend yield of 3.09%. The yearly dividend amount is currently 6.24.
What is the ChartMill technical and fundamental rating of ABBV stock?
ABBV has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Where is ABBVIE INC (ABBV) stock traded?
ABBV stock is listed on the New York Stock Exchange exchange.
What sector and industry does ABBVIE INC belong to?
ABBVIE INC (ABBV) operates in the Health Care sector and the Biotechnology industry.
When is the next dividend date for ABBVIE INC (ABBV)?
The next ex-dividend date for ABBVIE INC (ABBV) is January 16, 2026.